Myeloablative chemotherapy and stem cell transplantation in myeloma or primary amyloidosis with renal involvement

Kidney International

Volumn 68, Issue 4, 2005, Pages 1464-1471

  Gertz, Morie A ^a   Leung, Nelson ^b   Lacy, Martha Q ^b   Dispenzieri, Angela ^b  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

High dose chemotherapy; Multiple myeloma; Nephrotic syndrome; Primary amyloidosis; Renal failure; Stem cell transplantation

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAMETHYLENE PHOSPHONIC ACID HOLMIUM 166; ANTINEOPLASTIC AGENT; BUSULFAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIMETHYL SULFOXIDE; DIURETIC AGENT; DOXORUBICIN; GROWTH FACTOR; MELPHALAN; PREDNISOLONE; RADIOISOTOPE; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE KIDNEY FAILURE; ALLOGENEIC STEM CELL TRANSPLANTATION; ANURIA; AREA UNDER THE CURVE; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACTEREMIA; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG HALF LIFE; DRUG MEGADOSE; GASTROINTESTINAL HEMORRHAGE; GRAFT VERSUS HOST REACTION; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART INFARCTION; HEMODIALYSIS; HEMORRHAGIC CYSTITIS; HUMAN; HYPOTENSION; INTESTINAL BLEEDING; KIDNEY AMYLOIDOSIS; KIDNEY FAILURE; KIDNEY INJURY; LUNG ASPERGILLOSIS; LUNG DISEASE; LYMPHOPROLIFERATIVE DISEASE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MEMBRANOUS GLOMERULONEPHRITIS; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; MULTIPLE ORGAN FAILURE; MYELOABLATIVE CONDITIONING; NEPHROLOGIST; NEPHROTIC SYNDROME; NEPHROTOXICITY; NEUROLOGIC DISEASE; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; RENAL REPLACEMENT THERAPY; SEPSIS; SEPTIC SHOCK; STEM CELL TRANSPLANTATION; THROMBOTIC THROMBOCYTOPENIC PURPURA; TOXIC MEGACOLON; TOXICITY; WHOLE BODY RADIATION;

AMYLOIDOSIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MULTIPLE MYELOMA; MYELOABLATIVE AGONISTS; NEPHROTIC SYNDROME;

EID: 31644437496     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.00559.x     Document Type: Article

References (51)

1. JEMAL A, TIWARI RC, MURRAY T, et al: Cancer statistics, 2004. CA Cancer J Clin 54:8-29, 2004
2. KYLE RA, GERTZ MA, WITZIG TE, et al: Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78:21-33, 2003
3. ALEXANIAN R, BARLOGIE B, DIXON D: Renal failure in multiple myeloma: pathogenesis and prognostic implications. Arch Intern Med 150:1693-1695, 1990
4. ATTAL M, HAROUSSEAU J-L, STOPPA AM, et al, FOR THE INTERGROUPE FRANÇAIS DU MYÉLOME: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 335:91-97, 1996
5. CHILD JA, MORGAN GJ, DAVIES FE, et al: High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348:1875-1883, 2003
6. ATTAL M, HAROUSSEAU JL, FACON T, et al: Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 349:2495-2502, 2003
7. PALUMBO A, BRINGHEN S, PETRUCCI MT, et al: Intermediate-dose melphalan improves survival of myeloma patients aged 50-70: Results of a randomised controlled trial. Blood 104:3052-3057, 2004
8. REECE DE, BREDESON C, PEREZ WS, et al: Autologous stem cell transplantation in multiple myeloma patients <60 vs. ≥60 years of age. Bone Marrow Transplant 32:1135-1143, 2003
9. 2). Leukemia 18:133-138, 2004
10. PHILLIPS GL, MEISENBERG B, REECE DE, et al: Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: A phase I study. Biol Blood Marrow Transplant 10:473-483, 2004
11. KERGUERIS MF, MILPIED N, MOREAU P, et al: Pharmacokinetics of high-dose melphalan in adults: Influence of renal function. Anticancer Res 14:2379-2382, 1994
12. TRICOT G, ALBERTS DS, JOHNSON C, et al: Safety of autotransplants with high-dose melphalan in renal failure: A pharmacokinetic and toxicity study. Clin Cancer Res 2:947-952, 1996
13. 166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: Results of two phase 1/2 trials. Blood 102:2684-2691, 2003
14. 166Ho-DOTMP. Cancer Biother Radiopharm 18:225-230, 2003
15. BALLESTER OF, TUMMALA R, JANSSEN WE, et al: High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiency. Bone Marrow Transplant 20:653-656, 1997
16. SAN MIGUEL JF, LAHUERTA JJ, GARCIA-SANZ R, et al: Are myeloma patients with renal failure candidates for autologous stem cell transplantation? Hematol J 1:28-36, 2000
17. TOSI P, ZAMAGNI E, RONCONI S, et al: Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure. Leukemia 14:1310-1313, 2000
18. BADROS A, BARLOGIE B, SIEGEL E, et al: Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 114:822-829, 2001
19. BLADÉ J, FERNANDEZ-LLAMA P, BOSCH F, et al: Renal failure in multiple myeloma: Presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 158:1889-1893, 1998
20. FASSAS A, TRICOT G: Results of high-dose treatment with autologous stem cell support in patients with multiple myeloma. Semin Hematol 38:231-242, 2001
21. GERTZ M: Transplantation for multiple myeloma: Pertinent questions. Blood 102:3472-3475, 2003
22. BLADÉ J, VESOLE DH, GERTZ M: High-dose therapy in multiple myeloma. Blood 102:3469-3470, 2003
23. TAURO S, CLARK FJ, DUNCAN N, et al: Recovery of renal function after autologous stem cell transplantation in myeloma patients with end-stage renal failure. Bone Marrow Transplant 30:471-473, 2002
24. IMRIE K, ESMAIL R, MEYER RM: The role of high-dose chemotherapy and stem-cell transplantation in patients with multiple myeloma: a practice guideline of the Cancer Care Ontario Practice Guidelines Initiative. Ann Intern Med 136:619-629, 2002
25. HAHN T, RONDEAU C, SHAUKAT A, et al: Acute renal failure requiring dialysis after allogeneic blood and marrow transplantation identifies very poor prognosis patients. Bone Marrow Transplant 32:405-410, 2003
26. ROSSI L, CARDARELLI F, VAMPA ML, et al: Membranous glomerulonephritis after haematopoietic cell transplantation for multiple myeloma. Nephron 88:260-263, 2001
27. REGO F, ALCANTARA P, BUINHO F, et al: Autologous peripheral stem cell transplantation for multiple myeloma in a patient with a 10 year-old kidney transplant: Case report and clinical issues. Transplant Proc 35:1102-1104, 2003
28. SUN X, PETERSON LC, GONG Y, et al: Post-transplant plasma cell myeloma and polymorphic lymphoproliferative disorder with monoclonal serum protein occurring in solid organ transplant recipients. Mod Pathol 17:389-394, 2004
29. ZEIER M, PERZ J, LINKE RP, et al: No regression of renal AL amyloid in monoclonal gammopathy after successful autologous blood stem cell transplantation and significant clinical improvement. Nephrol Dial Transplant 18:2644-2647, 2003
30. VAN GAMEREN II, HAZENBERG BP, JAGER PL, et al: AL amyloidosis treated with induction chemotherapy with VAD followed by high dose melphalan and autologous stem cell transplantation. Amyloid 9:165-174, 2002
31. GERTZ MA, LACY MQ, DISPENZIERI A, et al: Stem cell transplantation for the management of primary systemic amyloidosis. Am J Med 113:549-555, 2002
32. ZENHAUSERN R, TOBLER A, LEONCINI L, et al: Fatal cardiac arrhythmia after infusion of dimethyl sulfoxide-cryopreserved hematopoietic stem cells in a patient with severe primary cardiac amyloidosis and end-stage renal failure. Ann Hematol 79:523-526, 2000
33. GERTZ MA, LACY MQ, DISPENZIERI A: Immunoglobulin light chain amyloidosis and the kidney. Kidney Int 61:1-9, 2002
34. COMENZO RL, GERTZ MA: Autologous stem cell transplantation for primary systemic amyloidosis. Blood 99:4276-4282, 2002
35. HAYES-LATTIN BM, CURTIN PT, FLEMING WH, et al: Toxic megacolon: A life-threatening complication of high-dose therapy and autologous stem cell transplantation among patients with AL amyloidosis. Bone Marrow Transplant 30:279-285, 2002
36. COMENZO RL: Hematopoietic cell transplantation for primary systemic amyloidosis: What have we learned. Leuk Lymphoma 37:245-258, 2000
37. GERTZ MA, LACY MQ, DISPENZIERI A: Myeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis: A status report. Bone Marrow Transplant 25:465-470, 2000
38. LEUNG N, SLEZAK JM, BERGSTRALH EJ, et al: Acute renal insufficiency after high-dose melphalan in patients with primary systemic amyloidosis during stem cell transplantation. Am J Kidney Dis 45:102-111, 2005
39. SNANOUDJ R, MAMZER-BRUNEEL MF, HERMINE O, et al: Recovery of acute renal failure and nephrotic syndrome following autologous stem cell transplantation for primary (AL) amyloidosis. Nephrol Dial Transplant 18:2175-2177, 2003
40. CASSERLY LF, FADIA A, SANCHORAWALA V, et al: High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal disease. Kidney Int 63:1051-1057, 2003
41. BLUM W, KHOURY H, LIN HS, et al: Primary amyloidosis patients with significant organ dysfunction tolerate autologous transplantation after conditioning with single-dose total body irradiation alone: A feasibility study. Biol Blood Marrow Transplant 9:397-404, 2003
42. SHERIF AM, REPAIE AF, SOBH MA, et al: Long-term outcome of live donor kidney transplantation for renal amyloidosis. Am J Kidney Dis 42:370-375, 2003
43. LEUNG N, GRIFfIN MD, DISPENZIERI A, et al: Living donor kidney and autologous stem cell transplantation for primary systemic amyloidosis (AL) with predominant renal involvement. Am J Transplant 5:1660-1670, 2005
44. DISPENZIERI A, LACY MQ, KYLE RA, et al: Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol 19:3350-3356, 2001
45. DISPENZIERI A, KYLE RA, LACY MQ, et al: Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: A case-control study. Blood 103:3960-3963, 2004
46. SELDIN DC, ANDERSON JJ, SANCHORAWALA V, et al: Improvement in quality of life of patients with AL amyloidosis treated with high dose melphalan and autologous stem cell transplantation. Blood 104:1888-1893, 2004
47. LEUNG N, LAGER DJ, GERTZ MA, et al: Long-term outcome of renal transplantation in light-chain deposition disease. Am J Kidney Dis 43:147-153, 2004
48. ROYER B, ARNULF B, MARTINEZ F, et al: High dose chemotherapy in light chain or light and heavy chain deposition disease. Kidney Int 65:642-648, 2004
49. MEAD GP, CARR-SMITH HD, DRAYSON MT, et al: Serum free light chains for monitoring multiple myeloma. Br J Haematol 126:348-354, 2004
50. LACHMANN HJ, GALLIMORE R, GILLMORE JD, et al: Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 122:78-84, 2003
51. ABRAHAM RS, KATZMANN JA, CLARK RJ, et al: Quantitative analysis of serum free light chains: A new marker for the diagnostic evaluation of primary systemic amyloidosis. Am J Clin Pathol 119:274-278, 2003